Sunitinib Rechallenge After Other Targeted Therapies in Metastatic Renal Cell Carcinoma Patients: A Single-Center, Retrospective Study.
Krisztián NagyiványiBarna BudaiFruzsina GyergyayZsófia KüronyaKrisztina BíróLajos GécziPublished in: Clinical drug investigation (2019)
Sunitinib rechallenge is a feasible and tolerable option with clinical benefit in selected mRCC patients.